Literature DB >> 12669107

Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives.

Shrinivas K Kulkarni1, Pattipati S Naidu.   

Abstract

Nearly 1% of the world population suffers from schizophrenia, and neuroleptics are the major class of drugs used to treat this disorder. Neuroleptics are associated with wide variety of extrapyramidal side effects, such as akathesia, dystonia, neuroleptic malignant syndrome, Parkinson-ism and tardive dyskinesia. Despite the awareness that neuroleptics could cause extrapyramidal side effects, these drugs remain the most effective means of treating schizophrenia and Tourette's syndrome, as well as for the management of behavioral disorders in developmentally disabled individuals. Tardive dyskinesia is a complex hyperkinetic syndrome consisting of choriform, athetoid or rhythmically abnormal involuntary movements. Estimates of the prevalence rate of tardive dyskinesia in patients receiving neuroleptics range from 0.5-70%, with an average prevalence rate of 24%. Despite much research, the pathogenesis of tardive dyskinesia remains elusive. So far, various neurochemical hypotheses have been proposed for the development of tardive dyskinesia. These include dopaminergic hypersensitivity, disturbed balance between dopamine and cholinergic systems, dysfunctions of striatonigral GABAergic neurons and excitotoxicity. Similarly, different suppressive agents have been tried with limited success. Recently, the role of oxidative stress and structural abnormality in the pathophysiology of tardive dyskinesia has gained much impetus. Induction of free radicals by neuroleptic drugs leading to the oxidative stress and resultant structural abnormality could be the key factor in the pathogenesis of tardive dyskinesia. This hypothesis has been supported by numerous reports that chronic neuroleptic treatment increases free radical production and causes structural damage. More recently, the genetic vulnerability for the predisposition for the development of tardive dyskinesia, i.e., pharmacogenetic aspect of tardive dyskinesia, is also gaining impetus as a research area, and is discussed in detail in this article. (c) Prous Science 2003. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669107     DOI: 10.1358/dot.2003.39.1.799430

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  8 in total

Review 1.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

Review 2.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

3.  An update on tardive dyskinesia: from phenomenology to treatment.

Authors:  Olga Waln; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-07-12

4.  Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis: A nationwide study in Taiwan.

Authors:  Bi-Chun Duan; Wen-Chin Weng; Kuang-Lin Lin; Lee Chin Wong; Sung-Tse Li; Mei-Hsin Hsu; Jainn-Jim Lin; Pi-Chaun Fan; Ming-I Lin; Nan-Chang Chiu; Yu-Ching Lin; Huei-Shyong Wang; Kun-Long Hung; Wang-Tso Lee
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

Review 5.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

6.  Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

Authors:  Shaina Musco; Laura Ruekert; Jaclyn Myers; Dennis Anderson; Michael Welling; Elizabeth Ann Cunningham
Journal:  J Clin Psychopharmacol       Date:  2019 Jul/Aug       Impact factor: 3.153

Review 7.  Second-generation antipsychotics and extrapyramidal adverse effects.

Authors:  Nevena Divac; Milica Prostran; Igor Jakovcevski; Natasa Cerovac
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

8.  Natural Medicines for Psychotic Disorders: A Systematic Review.

Authors:  H J Rogier Hoenders; Agna A Bartels-Velthuis; Nina K Vollbehr; Richard Bruggeman; Henderikus Knegtering; Joop T V M de Jong
Journal:  J Nerv Ment Dis       Date:  2018-02       Impact factor: 2.254

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.